Blueprint Medicines: Rampant Growth Mostly Priced In [Seeking Alpha]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Seeking Alpha
AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues. This is my initial Blueprint Medicines ( NASDAQ: BPMC ) article. Blueprint is a commercial stage biotech which is pegging potential blockbuster revenues for AYVAKIT/AYVAKYT (avapritinib), its one FDA approved product. With its hefty market cap anticipating Recommended For You Recommended For You About BPMC Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Stephens. They set an "overweight" rating and a $140.00 price target on the stock.MarketBeat
- Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at Leerink Partnrs from an "underperform" rating to a "market perform" rating.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $121.00 to $168.00. They now have a "buy" rating on the stock.MarketBeat
BPMC
Earnings
- 5/2/24 - Beat
BPMC
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/15/24 - Form 144
- BPMC's page on the SEC website